Trade policy support in regard to non-tariff trade barriers
Registered Lobbyists (1)
JUSTIN MCCARTHY ●NEW— Assistant U.S. Trade Representative, 2005-2007; Special Assistant to the President; 2007-2008
IDs
Filing UUID:395c8f26-4e9b-4a0b-b43b-2aa265e366fd
Registrant ID:401106546
Client ID:67227
2025-06-17
BRIGHTSPRING HEALTH SERVICES
BRIGHTSPRING HEALTH SERVICES
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Pharmacy and provider issues - various; Pharmacy and provider issues - various; Pharmacy and provider issues - various
Registered Lobbyists (1)
ESME GREWAL ●NEW
IDs
Filing UUID:3075c0aa-7201-437e-8c9d-b546f1d936e1
Registrant ID:401109655
Client ID:67178
2025-06-16
DGA GROUP GOVERNMENT RELATIONS LLC
VIIV HEALTHCARE
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Defense of U.S. pharmaceutical intellectual property rights and innovation incentives. Foreign trade and intellectual property.
Registered Lobbyists (2)
ANDRES GARCIA ●NEWJUSTIN MCCARTHY ●NEW— Assistant U.S. Trade Representative, 2005-2007; Special Assistant to the President, 2007-2008.
IDs
Filing UUID:16b9d594-ad23-40f1-a474-1f419160d811
Registrant ID:401106546
Client ID:66695
2025-06-13
RUBIN, TURNBULL & ASSOCIATES
USANTIBIOTICS
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Advocate on issues related to pharmaceuticals and drug regulation.
Registered Lobbyists (2)
HEATHER TURNBULL ●NEWWILLIAM RUBIN ●NEW
IDs
Filing UUID:3639d6ec-4c8f-442c-a2ac-3d3d77ccd6b7
Registrant ID:401106132
Client ID:67099
2025-06-13
RUBIN, TURNBULL & ASSOCIATES
USANTIBIOTICS
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Advocate on issues related to pharmaceuticals and drug regulation.
Registered Lobbyists (2)
HEATHER TURNBULL ●NEWWILLIAM RUBIN ●NEW
IDs
Filing UUID:832cba91-003a-459c-97e3-33e8415df65b
Registrant ID:401106132
Client ID:67099
2025-06-13
BALLARD PARTNERS
PUBLIX SUPER MARKETS, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Labor and hiring practice issues; compliance with environmental regulations; healthcare reforms impacting pharmacies.; Labor and hiring practice issues; compliance with environmental regulations; healthcare reforms impacting pharmacies.
Registered Lobbyists (3)
ALISON ANWAY ●NEW— LA to Senator Pat Roberts 2006-2010ANA CRUZ ●NEW— Regional Director to U.S. Senator Bill Nelson (2001-2002)BRIAN BALLARD ●NEW
IDs
Filing UUID:6eb91fe3-7e16-4588-860f-dd73947bce2f
Registrant ID:401104288
Client ID:67114
2025-06-12
AGIOS PHARMACEUTICALS
AGIOS PHARMACEUTICALS
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Pharmacy, Medicare/Medicaid, Health Issues; Pharmacy, Medicare/Medicaid, Health Issues; Pharmacy, Medicare/Medicaid, Health Issues
Registered Lobbyists (1)
AARON KRUPP ●NEW
IDs
Filing UUID:38ad3da1-dd2d-46f1-87bf-da64c5a66ea4
Registrant ID:401109657
Client ID:67079
2025-06-10
LEAVITT PARTNERS, LLC
ORCHARD THERAPEUTICS NORTH AMERICA
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Newborn screening and pharmaceuticals.
Registered Lobbyists (2)
CONNOR SHEEHEY ●NEW— Senate Finance: Senior Health Policy Advisor-Chair; Senior Health Policy Advisor-RM; Health Policy Advisor-RM; Deputy Legislative Director-Senate; Legislative Assistant-Senate; Deputy Legislative Assistant-Senate; Legislative Fellow-SenateMELISSA PFAFF ●NEW— Senate HELP: Senior Health Policy Advisor-Ranking Member (RM); Senior Policy Advisor-Chair; Health Policy Advisor-Chair; Prof Staff Member-Chair; Prof Staff Member-RM; Prof Staff Member RM-Senate Budget; Leg Corres-Senate; Staff Assistant-Senate
IDs
Filing UUID:28e4ecbd-ec26-41a3-8868-f119f541c972
Registrant ID:401103367
Client ID:67047
2025-06-10
KYOWA KIRIN, INC
KYOWA KIRIN, INC
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
FDA modernization policy issues General issues related to rare disease and clinical trials General issues related to diagnostics for patients with rare diseases Issues related to drug pricing Issues related to reform of pharmacy benefit managers Issues related to trade Issues related to Newborn Screening and Genetic Testing
Registered Lobbyists (1)
EDWARD BUCKLEY ●NEW
IDs
Filing UUID:8729b8cb-6077-455e-ab4f-70d57167fe18
Registrant ID:401109649
Client ID:67055
2025-05-30
MILLER STRATEGIES, LLC
GILEAD SCIENCES, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Issues related to pharmaceuticals and drug development.; Issues related to pharmaceuticals and drug development.; Issues related to pharmaceuticals and drug development.
Registered Lobbyists (3)
ASHLEY GUNN ●NEW— Special Asst to the President, Senior Director, White House Office of Cabinet Affairs.JAMES MIN ●NEW— Chief of Staff, Rep. Vince Fong; Chief of Staff, Office of the 20th District of California; Chief of Staff, Deputy Chief of Staff, and Counsel, Speaker Kevin McCarthy; Chief of Staff, Rep. Bill ThomasJEFFREY MILLER ●NEW
EMILIA DISANTO ●NEW— Deputy Inspector General, US Department of State; Chief of Staff, Federal Housing Finance Agency Office of Inspector General; Chief Investigative Counsel & Special Counsel, US Senate Committee on FinanceJAKARA EASON ●NEW
IDs
Filing UUID:7b23c0d3-4dd2-46d2-90ea-1199bcadf0b3
Registrant ID:65191
Client ID:66611
2025-05-07
MR. DAN CRIPPEN
AMGEN
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
pharmacy pricing, R&D, chronic disease
Registered Lobbyists (1)
DAN CRIPPEN ●NEW
IDs
Filing UUID:fbebef47-d31b-407b-a9f4-02b0072afd1e
Registrant ID:401109565
Client ID:66449
2025-04-25
FIRST PRINCIPLES STRATEGIES, LLC
HORIZON GOVERNMENT AFFAIRS ON BEHALF OF U.S. PHARMACOPEIAL CONVENTION
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Nonprofit organization focused on building trust in the supply of safe, quality medicines.
Registered Lobbyists (1)
JOSEPH MURRAY ●NEW— Senator Ron Johnson, Rep. Mark Meadows, and Republican Study Committee
IDs
Filing UUID:082627ff-8336-4c11-be29-07f043500ff9
Registrant ID:401104348
Client ID:66291
2025-04-25
OLD NORTH STRATEGIES, LLC
HORIZON GOVERNMENT AFFAIRS ON BEHALF OF U.S. PHARMACOPEIAL CONVENTION
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Nonprofit organization focused on building trust in the supply of safe, quality medicines
Registered Lobbyists (1)
JOSEPH KING ●NEW— former Deputy Chief of Staff Congressman Mark Meadows & former Sr. Advisor Congressman Greg Murphy, MD
IDs
Filing UUID:c99c6370-eac0-42c0-a60c-b8344d51c409
Registrant ID:401106174
Client ID:66304
2025-04-24
REVVITY, INC.
REVVITY, INC.
$0
$30,000
Filing Details
Type: ld2 • Year: 2025 Q2
Specific Issues
Diagnostic test reimbursement and policies Genomic sequencing T-Cell Immune Response Testing Proposals related to newborn screening Proposals related to pandemic preparedness FDA Medical Device Product policies H.R. 2810, Family Cord Blood Banking Act; Medical Device & Pharmaceutical Adjacent Tariff
Government Entities
Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, SENATE, Bureau of Industry and Security (BIS)
Registered Lobbyists (1)
LUIS TOVAR ●NEW
IDs
Filing UUID:33bca1b0-cbdd-4445-b089-32fef0fc71e0
Registrant ID:401105953
Client ID:208897
2025-04-23
HORIZON GOVERNMENT AFFAIRS
THE UNITED STATES PHARMACOPEIAL CONVENTION
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Prescription drug issues and prescription drug supply chain
Registered Lobbyists (4)
COLTON HENNING ●NEWJOE MURRAY ●NEWJOEL WHITE ●NEW— Former Staff Director, Ways & Means Health Subcommittee; L.A. for Rep. Jim Greenwood; L.A. for Rep. Chris ShaysWAYNE KING ●NEW
IDs
Filing UUID:1b574bc8-51d9-43b4-958c-46569fa1f29e
Registrant ID:315592
Client ID:66248
2025-04-22
NORTH SOUTH GOVERNMENT STRATEGIES, FKA JDM PUBLIC STRATEGIES, LLC
MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMER
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency,real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484; Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency,real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484; Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency,real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484; Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency,real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484; Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency,real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484
Registered Lobbyists (1)
ERIC SILVA ●NEW— Legislative Staff, Senate Environment and Public Works Committee and Senator James Jeffords
IDs
Filing UUID:675f6655-af62-4db2-8085-084482e2cdd8
Registrant ID:400689052
Client ID:66228
2025-04-17
FRONTLINE GOVERNMENT RELATIONS
EMPOWER PHARMACY
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Engage with federal agencies, members of Congress and congressional committees impacting pharmaceutical compounding and patient health issues.; Engage with federal agencies, members of Congress and congressional committees impacting pharmaceutical compounding and patient health issues.; Engage with federal agencies, members of Congress and congressional committees impacting pharmaceutical compounding and patient health issues.
Registered Lobbyists (1)
JOHN PENCE ●NEW
IDs
Filing UUID:c5b7ba88-51dc-4c09-8945-2ed30346733e
Registrant ID:401109481
Client ID:65940
2025-04-11
CORCORAN & ASSOCIATES, INC. DBA CORCORAN PARTNERS
ORCHARD THERAPEUTICS NORTH AMERICA
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Issues around health and pharmaceuticals.; Issues around health and pharmaceuticals.; Issues around health and pharmaceuticals.
Registered Lobbyists (2)
MICHAEL CORCORAN ●NEWROBERT BLAIR ●NEW
IDs
Filing UUID:239c47b0-da68-471c-80a9-fbc05b0cccad
Registrant ID:401109009
Client ID:65681
2025-04-07
THE VOGEL GROUP
NEPHRON PHARMACEUTICALS CORPORATION
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Issues relating to facility operations
Registered Lobbyists (2)
ADRIAN JEWETT ●NEWALEXANDER VOGEL ●NEW— Former Chief Counsel, Senate Majority Leader Bill Frist
IDs
Filing UUID:4fc2578c-1b33-4c53-ba8d-cd8c081af99a
Registrant ID:401104734
Client ID:202541
2025-03-31
LANTHEUS HOLDINGS, INC.
LANTHEUS HOLDINGS, INC.
$0
$420,000
Filing Details
Type: ld2 • Year: 2025 Q1
Specific Issues
HOPPS separate payment for diagnostic radiopharmaceuticals
Government Entities
Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Registered Lobbyists (1)
IRA GOLDMAN
IDs
Filing UUID:9f9143c2-a026-4544-937d-c9ed0ad7eacf
Registrant ID:401105198
Client ID:203388
2025-03-28
PARATEK PHARMACEUTICALS
PARATEK PHARMACEUTICALS
$0
$10,000
Filing Details
Type: ld2 • Year: 2025 Q1
Specific Issues
FY 26 DOD Appropriations FY 26 HHS Appropriations Biodefense Funding
Government Entities
Defense, Dept of (DOD), Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, SENATE
Registered Lobbyists (1)
BENJAMIN NOVAK
IDs
Filing UUID:0571fd7a-b582-4359-baa7-bd2e29d76dc4
Registrant ID:401109327
Client ID:64825
2025-03-27
MILLS BLACK LLP
POPULUS MEDIA, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Respond to Senate inquiry re pharmaceutical marketing; Respond to Senate inquiry re pharmaceutical marketing
Registered Lobbyists (1)
THOMAS MILLS ●NEW
IDs
Filing UUID:86465423-5d5e-4c0c-b358-38852bbe0856
Registrant ID:401106427
Client ID:65261
2025-03-27
CHECKMATE GOVERNMENT RELATIONS
REGENERON PHARMACEUTICALS INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Issues related to healthcare.
Registered Lobbyists (2)
CHARLES MCDOWELL ●NEWFREDERICK VAUGHAN ●NEW— Principal Deputy Asst. Secretary, Treasury Dept.; Deputy Asst. Secretary, Treasury Dept.; Senior Counsel, House Financial Services Cmte.; Associate Director, The White House; Confidential Asst., Office of Management & Budget; Writer, The White House